Oppenheimer Issues Positive Forecast for Opus Genetics (NASDAQ:IRD) Stock Price

Opus Genetics (NASDAQ:IRD) had its price objective raised by equities research analysts at Oppenheimer from $10.00 to $20.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective indicates a potential upside of 249.04% from the stock’s previous close.

IRD has been the topic of several other research reports. BTIG Research reiterated a “buy” rating and issued a $12.00 price objective on shares of Opus Genetics in a report on Wednesday. Guggenheim initiated coverage on Opus Genetics in a research report on Thursday, June 4th. They set a “buy” rating and a $16.00 price target on the stock. Citizens Jmp reissued a “market outperform” rating and set a $11.00 price target on shares of Opus Genetics in a research report on Monday, June 15th. Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, Chardan Capital set a $16.00 price objective on shares of Opus Genetics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.69.

Opus Genetics Trading Up 32.0%

Shares of IRD traded up $1.39 during mid-day trading on Wednesday, reaching $5.73. The company’s stock had a trading volume of 53,465,596 shares, compared to its average volume of 1,276,095. The stock has a market cap of $473.58 million, a PE ratio of -4.24 and a beta of 0.58. Opus Genetics has a 52 week low of $1.32 and a 52 week high of $7.07. The company’s fifty day moving average price is $3.79 and its two-hundred day moving average price is $4.29.

Opus Genetics (NASDAQ:IRD) last released its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. Research analysts anticipate that Opus Genetics will post -0.99 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Robert E. Gagnon sold 28,000 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total transaction of $127,120.00. Following the transaction, the chief financial officer owned 556,375 shares in the company, valued at $2,525,942.50. The trade was a 4.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of the stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the transaction, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 57,331 shares of company stock worth $213,749. Insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Opus Genetics in the second quarter worth $12,809,000. Nantahala Capital Management LLC bought a new position in shares of Opus Genetics in the 2nd quarter worth about $12,582,185. Trails Edge Capital Partners LP bought a new position in shares of Opus Genetics in the 2nd quarter worth about $11,276,434. Balyasny Asset Management L.P. purchased a new position in Opus Genetics during the 4th quarter valued at about $5,463,000. Finally, Millennium Management LLC bought a new stake in Opus Genetics during the fourth quarter worth about $4,025,000. Institutional investors own 14.97% of the company’s stock.

Key Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Positive Phase 1/2 results: All five participants in the low-dose Cohort 1 of the BIRD-1 trial showed clinically meaningful improvement in visual function, while four participants demonstrated structural improvements. Three of five patients achieved meaningful best-corrected visual acuity gains, and three of four evaluable patients improved retinal sensitivity. No serious adverse events or dose-limiting toxicities were reported. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: Regulatory and development progress: Following a successful FDA Type C meeting, the agency aligned with a potential pivotal endpoint combining at least a three-decibel microperimetry improvement with patient-reported outcomes. Opus expects to complete Cohort 2 dosing in the fourth quarter of 2026, report initial data in the second quarter of 2027, and potentially begin Phase 3 dosing in 2027. The company also expects its cash runway to extend into 2029.
• Positive Sentiment: Analyst support strengthened: HC Wainwright reaffirmed a Buy rating with an $8 price target, while BTIG Research maintained Buy with a $12 target and Chardan Capital reiterated Buy with a $13 target. These targets imply substantial potential upside from recent trading levels and reinforce investor confidence in the program.
• Positive Sentiment: Speculative buying increased: Investors purchased 4,820 call options, roughly 681% above typical volume, signaling heightened bullish positioning. The stock also experienced exceptionally heavy trading activity as the clinical update attracted attention.
• Neutral Sentiment: Institutional interest: BlackRock, Trails Edge Capital Partners, Nantahala Capital Management and other funds recently established or increased positions. Institutional and hedge-fund ownership is approximately 15%, providing some additional sponsorship but not guaranteeing future performance.
• Negative Sentiment: Insider sale: CFO Robert Gagnon sold 28,000 shares for $127,120 to cover tax withholding tied to vested equity awards. The transaction reduced his holdings by 4.79%, although he continues to own more than 556,000 shares.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.